PMID- 25120661
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211021
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 8
IP  - 3
DP  - 2014 Sep
TI  - Clinical significance of aberrant mammalian target of rapamycin expression in 
      stage IIIB colon cancer.
PG  - 1080-1086
AB  - The aim of the present study was to investigate the significance of aberrant 
      expression of mammalian target of rapamycin (mTOR) and the activated form of mTOR 
      kinase, phosphorylated mTOR (pmTOR), in human stage IIIB colon cancer. The 
      expression of mTOR and pmTOR was detected by immunohistochemistry in the tumor 
      tissue of stage IIIB colon cancer patients. The association between the 
      expression of mTOR, pmTOR and clinicopathological parameters of patients was 
      analyzed. The positive expression of mTOR and pmTOR was observed to be higher in 
      75.5% (80/106) and 76.4% (81/106) of the 106 colon cancer specimens, compared 
      with the adjacent normal tissues. The high level of pmTOR expression was found to 
      be significantly higher in the invasive tumor front cells and resulted in a 
      higher risk of mortality. The results suggested that mTOR and pmTOR may be 
      promising clinical markers and present novel molecular targets for designing 
      novel therapeutic strategies to treat this malignancy.
FAU - Wen, Meiling
AU  - Wen M
AD  - Department of Medical Oncology, Affiliated Nanhua Hospital, Nan Hua University of 
      South China, Hengyang, Hunan 421002, P.R. China.
FAU - Li, Baoxiu
AU  - Li B
AD  - Department of Oncology, Guangzhou First People's Hospital, Guangzhou Medical 
      University, Guangzhou, Guangdong 510180, P.R. China.
FAU - Cao, Xiaofei
AU  - Cao X
AD  - Department of Oncology, Guangzhou First People's Hospital, Guangzhou Medical 
      University, Guangzhou, Guangdong 510180, P.R. China.
FAU - Weng, Chengyin
AU  - Weng C
AD  - Department of Oncology, Guangzhou First People's Hospital, Guangzhou Medical 
      University, Guangzhou, Guangdong 510180, P.R. China.
FAU - Wu, Yong
AU  - Wu Y
AD  - Department of Oncology, Guangzhou First People's Hospital, Guangzhou Medical 
      University, Guangzhou, Guangdong 510180, P.R. China.
FAU - Fang, Xisheng
AU  - Fang X
AD  - Department of Oncology, Guangzhou First People's Hospital, Guangzhou Medical 
      University, Guangzhou, Guangdong 510180, P.R. China.
FAU - Zhang, Xiaoshi
AU  - Zhang X
AD  - State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-Sen 
      University, Guangzhou, Guangdong 510275, P.R. China.
FAU - Liu, Guolong
AU  - Liu G
AD  - Department of Oncology, Guangzhou First People's Hospital, Guangzhou Medical 
      University, Guangzhou, Guangdong 510180, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20140625
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC4114703
OTO - NOTNLM
OT  - colon cancer
OT  - mammalian target of rapamycin
OT  - molecular target therapy
OT  - prognosis
EDAT- 2014/08/15 06:00
MHDA- 2014/08/15 06:01
PMCR- 2014/06/25
CRDT- 2014/08/15 06:00
PHST- 2013/11/26 00:00 [received]
PHST- 2014/05/23 00:00 [accepted]
PHST- 2014/08/15 06:00 [entrez]
PHST- 2014/08/15 06:00 [pubmed]
PHST- 2014/08/15 06:01 [medline]
PHST- 2014/06/25 00:00 [pmc-release]
AID - ol-08-03-1080 [pii]
AID - 10.3892/ol.2014.2285 [doi]
PST - ppublish
SO  - Oncol Lett. 2014 Sep;8(3):1080-1086. doi: 10.3892/ol.2014.2285. Epub 2014 Jun 25.